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OBJECTIVES We assessed the effect of glycoprotein IIb/IIIa inhibition (GPI) on microvascular flow after
coronary occlusion/reperfusion using quantitative myocardial contrast echocardiography
(QMCE).
BACKGROUND Platelets may play a major role in the dissociation of epicardial artery recanalization and
tissue-level reperfusion, referred to as the “no-reflow phenomenon.” Therefore, GPI might
improve myocardial reperfusion, distinct from its effects on epicardial patency.
METHODS Three-hour occlusion of the left anterior descending coronary artery (LAD) was followed by
3-h reperfusion in 16 open-chest dogs: 8 controls and 8 given a continuous infusion of the
GPI tirofiban, starting 45 min before LAD reopening. Perfusion of the LAD bed was
quantified by the rate of intensity rise (b) by QMCE; myocardial blood flow (MBF) was
assessed by fluorescent microspheres.
RESULTS No differences in b or MBF were observed within the risk area between the control and GPI
groups at baseline or occlusion. However, b and MBF were higher in GPI dogs than in
controls during reperfusion, despite similar epicardial flow (p  0.05 at 30, 60, and 90 min;
p  NS at 180 min). Infarct area size was significantly reduced in GPI dogs compared with
non-treated dogs (26.9  10.5% vs. 49.0  11.1% of at-risk area, respectively).
CONCLUSIONS As demonstrated by QMCE, GPI improves microvascular flow and reduces the infarct area
after coronary occlusion/reperfusion, independent of epicardial flow. These data demonstrate
the usefulness of QMCE in assessing microvascular flow, provide novel evidence for the role
of platelets in the early phase of reperfusion injury, and show that GPI is of value in preserving
microvascular perfusion after coronary reperfusion. (J Am Coll Cardiol 2004;43:276–83)
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Reperfusion strategies have led to a substantial improve-
ment in the prognosis of patients with acute myocardial
infarction (MI). However, the beneficial effect of successful
restoration of epicardial coronary flow on myocardial salvage
may be offset by inadequate tissue perfusion, a condition
referred to as the “no-reflow phenomenon” (1–3). Myocar-
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dial contrast echocardiography (MCE), which can provide
information on tissue-level perfusion, has demonstrated that
even in the presence of Thrombolysis In Myocardial Infarc-
tion (TIMI) flow grade 3, tissue-level perfusion may still be
severely reduced. Moreover, significant improvement in
myocardial function has been demonstrated to occur only in
the presence of MCE reflow.
The mechanism responsible for the no-reflow phenom-
enon is uncertain and is likely multifactorial. Due to the
potential for thrombus formation and release of vasoactive
substances, it has been suggested that platelets may play a
major role in the dissociation of epicardial artery recanali-
zation and tissue-level reperfusion (4). However, the role of
platelets in reperfusion injury, independent of epicardial
thrombosis and embolization, remains to be determined.
Similarly, although data exist that inhibition of the platelet
glycoprotein IIb/IIIa receptor prevents abrupt re-occlusion
after percutaneous coronary revascularization procedures
and improves TIMI flow rates in acute coronary syndrome
patients, the ability of glycoprotein IIb/IIIa inhibition
(GPI) to enhance flow at the microvascular level after
coronary reperfusion has not been determined (5,6).
We have recently shown that quantitative parameters
derived from refilling curves generated from quantitative
myocardial contrast echocardiography (QMCE) are closely
correlated to myocardial blood flow (MBF). Accordingly,
QMCE enables evaluation of flow in the coronary micro-
vasculature (7,8). In the present study, we employed
QMCE to examine whether glycoprotein IIb/IIIa inhibi-
tion (GPI) improves microvascular flow and thereby reduces
infarct size in an animal model of coronary occlusion/
reperfusion.
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METHODS
Animal preparation. The present study was approved by
the University of California-San Diego, Animal Research
Committee and conformed to the “Position of the Ameri-
can Heart Association on Research Animal Use,” adopted
by the Association in November 1984. Sixteen mongrel
dogs (26.1  1.9 kg) were anesthetized and ventilated to
keep arterial blood gases and pH within normal limits. The
right femoral artery and vein were cannulated for arterial
pressure monitoring and contrast agent injection, respec-
tively. The heart was exposed through a left lateral thora-
cotomy and suspended in a pericardial cradle. The proximal
portion of the left anterior descending coronary artery
(LAD) was dissected free from the surrounding tissue. An
atraumatic vascular clamp produced coronary occlusion of
the proximal LAD.
Experimental protocol. After a period of stabilization after
instrumentation, 3-h proximal LAD occlusion was followed
by 3-h reperfusion in 16 open-chest dogs: 8 controls and 8
given a continuous infusion of tirofiban (Aggrastat, Merck
& Co., Whitehouse Station, New Jersey) at 3 g/kg/min,
starting 45 min before LAD reopening (9–11). Hemody-
namic measurements, MBF, coronary flowmeter, and real-
time MCE data were acquired at baseline, immediately
before release of occlusion (180 min), and at 30, 60, 90, and
180 min of reperfusion.
Real-time imaging with MCE. Echocardiography was
performed with a commercial instrument (HDI 5000,
Philips Ultrasound, Andover, Massachusetts) using a broad-
band 4- to 2-MHz transducer. Color-coded harmonic
power-pulse inversion images were obtained with ultra-
sound transmitted at 2 MHz and received at 4 MHz in the
short-axis papillary muscle view, using low-energy (me-
chanical index  0.1) real-time imaging at 15 frames/s
(12,13). The pulse repetition frequency was fixed at 2,500
Hz. Instrument settings were held constant for each exper-
iment. A latex bag filled with degassed saline functioned as
an acoustic interface between the heart and transducer,
which was positioned to image the LAD perfusion territory.
SonoVue (Bracco Inc., Geneva, Switzerland) was continu-
ously infused at a rate of 30 ml/h by a gently agitated
infusion pump. Recordings were obtained 2 min after
initiating infusion to ensure that plateau intensity had been
reached. The MCE refilling sequences were recorded; they
consisted of high-energy (mechanical index  0.8) fast
low-angle shot (FLASH) frames to destroy microbubbles,
followed by 15 cardiac cycles of refilling.
Image analysis. The raw image data were digitally captured
and analyzed off-line using HDI laboratory software (Philips
Ultrasound). Perfusion of the LAD bed was quantified by
fitting intensity data of end-systolic images to an exponential
function: y  A (1  ebt), where y is the signal intensity at
any given time; A is the plateau signal intensity that reflects the
microvascular cross-sectional area or myocardial blood volume;
b is the rate of signal intensity rise (slope of curve) that reflects
myocardial microbubble velocity; and t is the time after
FLASH. The b parameter was used to estimate perfusion.
Transmural regions of interest that encompassed the LAD
perfusion territory were selected, excluding high-intensity sig-
nals from the epicardium and endocardium.
The myocardial risk area was identified as the region of
unopacified myocardium by MCE during coronary occlu-
sion. To measure the risk area size from MCE images, the
area of the largest clearly demarcated myocardial opacifica-
tion defect at 180 min of LAD occlusion was manually
traced for the final three end-diastolic images of the
15-cycle FLASH refilling sequence (14). Also, to measure
the infarct area size from MCE, the myocardial opacifica-
tion defect at 180 min of reperfusion was traced for the final
three end-diastolic images. The infarct area size from MCE
was expressed as the percent of the area at risk.
Measurements of LAD flow and MBF. Epicardial LAD
flow was measured by a Doppler flowmeter. A transit-time
flow probe connected to a digital flowmeter (series 2RB and
model T201, Transonics System, Ithaca, New York) was
placed snugly around the proximal LAD. Epicardial LAD
flow and MBF were measured at baseline, immediately before
release of occlusion (180 min), and at 30, 60, 90, and 180 min
after release of occlusion by injection of fluorescent micro-
spheres (Molecular Probes, Eugene, Oregon) into the left
atrium, while reference blood samples were withdrawn from
the femoral artery. For every injection, a different fluorescent
wavelength was used to allow for independent assessment of
flow at the different time points. After the animal was
euthanized, the heart was sliced, and the cross-sectional seg-
ment corresponding to the short-axis image was cut into 12
wedge-shaped transmural tissue pieces, each of which was
divided into endocardial and epicardial segments. Transmural
MBF to 12 wedge-shaped pieces was calculated as the quotient
of the summed flows to the individual segments within that
piece and their combined weight. The MBF to the LAD beds,
defined by monastral blue dye injection, was then calculated by
averaging the transmural MBF in the pieces from LAD bed.
Infarct and risk area size. At the end of the experiment,
the LAD was re-occluded, and blue dye was injected into
the left atrium. With the guidance of long needles placed as
markers, a left ventricular short-axis slice (6 to 8 mm thick)
Abbreviations and Acronyms
b  rate of signal intensity rise
FLASH  fast low-angle shot
GPI  glycoprotein IIb/IIIa inhibition/inhibitor
LAD  left anterior descending coronary artery
MBF  myocardial blood flow
MCE  myocardial contrast echocardiography
MI  myocardial infarction
QMCE  quantitative myocardial contrast
echocardiography
TIMI  Thrombolysis In Myocardial Infarction
TTC  triphenyltetrazolium chloride
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was cut out at the same level at which the echocardiogram
was recorded. The risk area was delineated as that without
blue stain. To determine the infarct area, each slice was
incubated in 1.5% triphenyltetrazolium chloride (TTC) at
37°C for 15 min, and the unstained region with TTC was
planed (15). Blinded quantitative histologic analysis of the
risk segment was also performed by light microscopy to look
for platelets.
Statistical analysis. Data are expressed as the mean  SD.
Analyses of the data were performed in a blinded fashion.
Comparisons of data among all stages were performed using
repeated-measures analysis of variance. Comparisons of
multiple linear regression data between control and GPI
groups were performed using analysis of co-variance. Dif-
ferences were considered significant at p  0.05.
RESULTS
All experiments were completed successfully without signif-
icant hemodynamic changes or adverse events. Recordings
were technically adequate to allow full measurement and
analysis.
Signal intensity data provided by MCE. Measurements
of the b parameter by MCE, representing the rate of
intensity rise within the risk area, are summarized in
Table 1 for each group at baseline, occlusion, and after
coronary reperfusion. No significant differences in b were
observed between the control and GPI groups either at
baseline or with occlusion. However, b was significantly
reduced during occlusion, compared with baseline, in both
groups. During reperfusion, b improved in both groups but
was greater in GPI dogs than in controls (Fig. 1). This
difference reached statistical significance at 30, 60, and
90 min but not at 180 min of reperfusion.
Assessment of size of infarct area. The percent infarct
area of the total risk area derived by MCE was significantly
reduced in GPI dogs compared with controls (26.9 10.5%
vs. 49.0  11.1% of area at risk, p  0.01). Figure 2 shows
representative changes in end-systolic images after FLASH
obtained after 180 min of reperfusion in GPI and control
dogs. To validate MCE measurements of infarct size, the
percent myocardium of the total left ventricle manifesting an
opacification defect was compared with that measured by TTC
Table 1. Myocardial Contrast Echocardiographic, Myocardial Blood Flow, and Coronary Flow Data
Baseline Occlusion R-30 R-60 R-90 R-180
b (1/s)
Control (n  8) 0.39  0.03 0.06  0.01* 0.22  0.02* 0.25  0.04* 0.22  0.02* 0.25  0.05*
GPI (n  8) 0.41  0.04 0.07  0.01* 0.37  0.04† 0.36  0.03† 0.38  0.03† 0.33  0.03
Myocardial blood flow (%)
Control (n  8) 100  0 25.2  4.7* 67.8  8.7* 73.7  13.9* 64.1  10.7* 62.2  10.8*
GPI (n  8) 100  0 39.0  9.7* 95.6  10.2† 109.4  17.3† 92.8  11.8† 86.5  14.0
LAD flow (ml/min)
Control (n  8) 11.6  1.6 0* 12.6  2.4 14.0  2.8 12.9  2.2 9.6  3.2
GPI (n  8) 10.4  2.9 0* 10.5  2.7 11.4  3.8 11.2  5.0 9.5  3.0
*p  0.05 versus baseline value of each group. †p  0.05 versus control group at each stage. Data are expressed as the mean value  SD.
b  rate of intensity rise; GPI  glycoprotein IIb/IIIa inhibition; LAD  left anterior descending coronary artery; R-30, R-60, R-90, and R-180  reperfusion for 30, 60,
90, and 180 min, respectively.
Figure 1. Time course of changes in the rate of intensity rise (b) parameter measurements by myocardial contrast echocardiography within the risk area at
baseline, occlusion, and after coronary reperfusion for each control (n 8) and glycoprotein IIb/IIIa inhibitor (GPI) (n 8) group. *p 0.05 versus control
group at each stage. Data are expressed as the mean  SD. R-30, R-60, R-90, and R-180  reperfusion for 30, 60, 90, and 180 min, respectively.
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at 180-min reperfusion. Measurements of the size of the MCE
opacification defect closely correlated with those of the infarct
area by TTC (y 1.0x 1.3, r 0.94) (Fig. 3). Quantitative
histologic analysis of the risk segment, including the no-reflow
zones, failed to reveal platelet plugging of the microvasculature
in either control or GPI dogs.
LAD flow and MBF. Data on epicardial LAD flow by
Doppler and on MBF by microspheres at baseline,
180-min LAD occlusion, and after coronary reperfusion
are summarized in Table 1 for each group. The MBF
data during occlusion and reperfusion are expressed as a
percentage of the baseline value. During LAD occlusion,
Doppler flow and MBF within the risk area were severely
reduced from baseline in both groups. During reperfu-
sion, epicardial LAD flow returned to baseline in both
groups. Although MBF within the risk area continued to
be reduced in the control group after reperfusion, it
returned to baseline levels in the GPI dogs. Thus, no
differences in risk-area MBF were observed between
control and GPI groups at baseline or occlusion. How-
ever, at 30, 60, and 90 min of reperfusion, MBF in GPI
dogs was significantly higher than in controls (Fig. 4). At
180 min, the difference in MBF between the GPI and
control dogs was no longer statistically significant.
Figure 2. Representative end-systolic myocardial contrast echocardiography images by real-time imaging after high-energy fast low-angle shot (FLASH)
transmission at 180-min reperfusion in both control and glycoprotein IIb/IIIa inhibitor (GPI) dogs. Arrows show an opacification defect after FLASH
images. The defect size in the control group is larger than that in the GPI group.
Figure 3. Correlation between the size of the infarct area by triphenyltetrazolium chloride (TTC) and that by myocardial contrast echocardiography (MCE)
at 180-min reperfusion (control: n  4; glycoprotein IIb/IIIa inhibitor [GPI]: n  4). LV  left ventricle.
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Infarct size and MBF during occlusion. The canine
model has variable coronary collateral flow. Therefore,
infarct size, normalized as a percentage of the area at risk,
was plotted against the mean MBF of the risk area during
coronary occlusion for the control and GPI groups (Fig. 5).
A significant downward shift in the line of the inverse
relationship was observed in the GPI-treated group (p 
0.05). This result clearly shows that GPI has a true effect to
reduce infarct size.
DISCUSSION
In this study, we used QMCE, which reflects blood velocity
and volume in the microcirculation, to assess the effect of
tirofiban, a specific GPI (16), on tissue-level perfusion in a
dog model of occlusion/reperfusion. We demonstrated en-
hanced microvascular flow that was independent of epicar-
dial flow with GPI, particularly in the initial 90 min of
reperfusion. Furthermore, we observed that this increased
flow was associated with a reduction in infarct size. These
data are the first to directly establish that GPI exerts a
favorable effect on capillary perfusion after restoration of
flow in epicardial vessels.
Our study also provides important evidence for the role of
platelets in the early phase of reperfusion. Assessing the role
of platelets in reperfusion injury is confounded clinically
and, in some experimental models of MI, by the presence
Figure 4. Time course of changes in the myocardial blood flow within the risk area at baseline, occlusion, and after coronary reperfusion for the control
(n  8) and glycoprotein IIb/IIIa inhibitor (GPI) (n  8) groups. *p  0.05 versus control group at each stage. The data during occlusion and reperfusion
are expressed as the mean percentage of baseline  SD. R-30, R-60, R-90, and R-180  reperfusion for 30, 60, 90, and 180 min, respectively.
Figure 5. The relationship between infarct size at risk and mean myocardial blood flow (MBF) of risk area during coronary occlusion is illustrated for the
control (n  8) and glycoprotein IIb/IIIa inhibitor (GPI) (n  8) groups. Each point represents an individual dog. A significant downward shift in the
line of the inverse relationship was observed in the GPI-treated group (p  0.05).
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and possible microembolization of epicardial thrombus (17).
Indeed, using labeled platelets, microembolization has been
documented in a model of coronary thrombosis. Our data
implicate platelets in the mechanism of reperfusion injury,
even in the absence of coronary thrombosis.
Infarct vessel patency has traditionally has been viewed as
the hallmark of successful reperfusion. However, increasing
evidence indicates that, even in the presence of vessel
patency and seemingly normal flow, up to one-third of
patients do not have adequate reperfusion at the tissue level.
Inadequate tissue-level perfusion has been shown to corre-
late with a lack of myocardial salvage. Therefore, optimal
reperfusion can be redefined as restoration of both epicardial
and tissue-level perfusion (18–20). This study demonstrates
a role for GPI in enhancing the latter.
Previous studies have provided evidence of the beneficial
effect of GPI in acute coronary syndromes. It has been
shown that GPI improves the outcomes of patients with
acute coronary syndromes undergoing a primary percutane-
ous coronary intervention (21,22). In the Platelet Receptor
inhibition for Ischemic Syndrome Management in Patients
Limited by Unstable Signs and symptoms (PRISM-PLUS)
trial, the use of tirofiban was shown to reduce intracoronary
thrombus and improve TIMI flow (23). In the setting of
ST-segment elevation MI, GPI was shown to improve the
speed and efficacy of epicardial reperfusion in combination
with lytic therapy. In addition, GPI reduced the 30-day
incidence of death, re-infarction, and urgent target vessel
revascularization in the setting of primary stenting, albeit
with an increased risk of bleeding (24,25). Flow velocity in
the infarct-related artery has also been shown to be im-
proved with GPI with stenting (5).
Although the beneficial effects of GPI on the microvas-
culature have also been suggested, current studies have used
only indirect assessment, such as improvement in coronary
flow, resolution of ST-segments, and improvement in
myocardial salvage, to gain insight into the effects on the
microcirculation (5). The most direct evidence, to date,
has been in the setting of elective percutaneous coronary
intervention. In a substudy of the Enhanced Suppression
of the Platelet GP IIb/IIIa Receptor with Integrilin
Therapy (ESPRIT) trial, Gibson et al. (26) demonstrated
that coronary flow reserve was improved in the eptifibatide-
treated group, compared with placebo. Myocardial blush
was also assessed using a visual scale and also demonstrated
improvement. The QMCE data in our study directly
demonstrate that GPI enhances microcirculatory flow dur-
ing reperfusion.
Mechanism of the no-reflow phenomenon. The pro-
posed mechanism of the no-reflow phenomenon is multi-
factorial. Animal and postmortem histologic studies have
demonstrated varying degrees of small-vessel vasospasm,
endothelial gap and bleb formation, neutrophil plugging of
capillaries as well as microvascular compression from myo-
cytes, interstitial edema, and hemorrhage after recanaliza-
tion (1,27,28). Platelets have also been implicated as major
contributors to the no-reflow phenomenon by inducing
vascular injury and the loss of capillary autoregulation.
Platelet effects may be particularly important in the first
stage of reperfusion, referred to as the “microvascular
obstruction stage” (29). Additional reperfusion injury, me-
diated by neutrophils, free radical release, and edema for-
mation, is thought to occur in the second stage. Platelet
activation can lead to the formation of thrombi or distal
microemboli, and obstructive platelet aggregates within
myocardial capillaries have been observed both experimen-
tally and clinically in reperfused ischemic tissue (30–32).
Platelet degranulation has also been observed during reper-
fusion. Released platelet granules contain multiple vasoac-
tive and chemotactic mediators that can compound tissue
ischemia and increase neutrophil infiltration. Distal vaso-
constriction due to platelet activation may mediate the
deleterious influence of nonocclusive coronary thrombosis
on distal tissue perfusion (33,34). After experimental isch-
emia/reperfusion, coronary microvessels have been demon-
strated to exhibit increased vascular resistance, a finding that
led to the so-called “injury-spasm hypothesis,” perhaps
mediated by platelets (35). Thus, several mechanisms exist
by which GPI may be beneficial in the prevention of the
no-reflow phenomenon.
Quantifying tissue perfusion by QMCE in response to
GPI therapy. Quantitative MCE is a novel method to
assess myocardial perfusion; it can be performed repeatedly
throughout the course of acute MI. Contrast microbubbles
are excellent tracers of red blood cell kinetics. The method
to quantify MBF velocity is based on rapid destruction of
microbubbles by ultrasound and subsequent assessment of
the rate at which they are replenished into the myocardial
microcirculation contained in the imaging field.
Our results using QMCE show that GPI improves
microvascular flow and reduces infarct size after coronary
occlusion/reperfusion. Importantly, the improvement in
tissue-level perfusion in the GPI group compared with the
control group was demonstrated, despite equivalent epicar-
dial flow, as measured by Doppler. Presumably, the epicar-
dial flow not transiting the microcirculation in the controls
was accommodated by the extensive collateral channels
known to be present in dogs. The QMCE measurements
were further validated by microsphere and TTC data, with
a good correlation between MBF derived by microspheres
and b by QMCE.
Although the b parameter at 180 min of reperfusion was
greater in GPI dogs than in controls, this difference did not
reach statistical significance. These data are consistent with
the concept that platelets play a greater role in the no-reflow
phenomenon early after reperfusion rather than later. The
late loss of a GPI effect on tissue perfusion seen in our study
may have been caused by reperfusion injury, which is
thought to occur after the microvascular obstruction stage
(18). The use of other concomitant therapies, such as free
radical scavengers and anti-adhesion molecules, may be
necessary to protect the microcirculation from this late
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phenomenon. Although of lesser significance than the
difference at earlier time points, the effect at 180 min may
have been affected by our small sample size and may still be
of clinical importance, as evidenced by the reduction in
infarct size.
Infarct size and GPI. The data from this study also
demonstrated that GPI reduced infarct size. The favorable
effects on infarct size observed with GPI might have been
related to a more rapid restoration of MBF. The enhance-
ment of early reflow by GPI may promote the delivery of
blood to the risk area, thus reducing MI size, speeding
healing, and decreasing infarct expansion. In the TIMI-14
trial, the improvement in perfusion of the infarct-related
artery seen with additional administration of GPI was
greater at 60 min than at 90 min of reperfusion, suggesting
that GPI may accelerate the speed as well as enhance the
extent of epicardial reperfusion (24). Our results suggest
that the beneficial effects of GPI may be mediated not only
by a faster recanalization of the culprit epicardial vessel but
also by enhanced microvascular flow, resulting in a reduced
size of MI.
Study limitations. There are several limitations of this
study. These results were obtained using a canine model,
which has abundant natural collateral channels, and so may
not apply to patients with more severely impaired multives-
sel coronary disease. Heparin and/or lytic therapy was not
administered in this model, and hence the contribution of
GPI in combination with these agents was not assessed. We
did not measure platelet aggregation in our study animals;
therefore, the exact degree of platelet inhibition that corre-
sponds with the improvements in MBF and infarct size
cannot be determined. However, the dose of tirofiban
chosen has been shown to inhibit platelet aggregation in the
dog by 80%, a level documented to be necessary for
clinical benefit in both animal and human studies (9,36,37).
Because we assessed infarct size at 3-h reperfusion, the
ultimate infarct size may be larger, especially given the
possibility of further non–platelet-mediated reperfusion in-
jury. In addition, the infarct size by QMCE may change
with variation of the duration of ischemia. Finally, these
results were observed in a acute experimental setting, and no
long-term data are available.
Conclusions. Our study supports a role for platelets in
early reperfusion injury and demonstrates a benefit of GPI
on microvascular flow, even in the absence of overt coronary
thrombosis. Furthermore, coronary recanalization strategies
are focusing on new end points, with microvascular perfu-
sion being particularly important. This study also demon-
strates that QMCE can provide a direct approach to
assessing changes in tissue perfusion in response to GPI
therapy and, moreover, that it has the unique ability to
delineate the myocardial and microvascular level at which
these structural and physiologic changes occur after coro-
nary reperfusion.
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